213 related articles for article (PubMed ID: 38057871)
1. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Yang L; Zhang W; Yan Y
Aging (Albany NY); 2023 Jul; 15(13):6135-6151. PubMed ID: 37399661
[TBL] [Abstract][Full Text] [Related]
3. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J; Wang J; Chen X; Zhang L; Peng M
PeerJ; 2024; 12():e16819. PubMed ID: 38317842
[TBL] [Abstract][Full Text] [Related]
4. Constructed Risk Prognosis Model Associated with Disulfidptosis lncRNAs in HCC.
Jia X; Wang Y; Yang Y; Fu Y; Liu Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139458
[TBL] [Abstract][Full Text] [Related]
5. Disulfidptosis-related signature predicts prognosis and characterizes the immune microenvironment in hepatocellular carcinoma.
Tang J; Peng X; Xiao D; Liu S; Tao Y; Shu L
Cancer Cell Int; 2024 Jan; 24(1):19. PubMed ID: 38195525
[TBL] [Abstract][Full Text] [Related]
6. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
Chen X; Liang Q; Zhou Y
Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
[TBL] [Abstract][Full Text] [Related]
7. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
8. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
11. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile.
Wang T; Guo K; Zhang D; Wang H; Yin J; Cui H; Wu W
Int Immunopharmacol; 2023 Jul; 120():110368. PubMed ID: 37247499
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
13. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
[TBL] [Abstract][Full Text] [Related]
14. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
[TBL] [Abstract][Full Text] [Related]
15. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
16. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M
Front Immunol; 2023; 14():1198826. PubMed ID: 38035071
[TBL] [Abstract][Full Text] [Related]
17. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
18. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
[TBL] [Abstract][Full Text] [Related]
19. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
20. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
